REGENXBIO, Inc. RGNX 深 沪
等待开盘 05-12 09:30:00 美东时间
10.08
-0.485
-4.59%
华盛通- 最 高11.36
- 今 开10.71
- 成交量 141.44万股
- 最 低 9.295
- 昨 收 10.565
- 总市值 43.48万
- 52周最高 16.19
- 市盈率 静 3.46
- 换手率 3279.08%
- 52周最低 7.35
- 委 比 -99.68%
- 总股本 4.31万
- 历史最高 85.10
- 量 比 1.67
- 振 幅 19.55%
- 历史最低 1.10
- 每 手 1
- 风险率 2.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, raising trial design concerns and pushing the approval timeline.
02-10 21:51
FDA Clinical Hold Knocks REGENXBIO Stock
REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to abnormal tissue growth in one patient.
01-29 01:31
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Assessing Regenxbio: Insights From 5 Financial Analysts
In the latest quarter, 5 analysts provided ratings for Regenxbio (NASDAQ:RGNX), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewh...
2024-09-05 03:00
REGENXBIO Reports Data From Pivotal Dose Level Of RGX-121; Says data Showed Long-Term Systemic Effect
The company reported results from the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome. The results were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2...
2024-09-03 20:08
